Shares fell more than 8% in premarket trading. The company said it was halting the development program in light of disappointing preclinical studies. Shares fell more than 8% in premarket trading. The ...

-- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial operations; updated interim data readout timing to be provided at later date -- “Our priority is always ...